AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$BMY

What Could Derail Bristol Myers Squibb Stock?

Bristol Myers Squibb (BMY) stock rose 42.9% in the past year. Management warned of a $1.5B-$2B revenue drop for Eliquis in 2027 due to lost exclusivity in Europe. Eliquis generated $14.4B in 2025, 30% of total revenue. Growth medicines revenue increased 12% in Q3 2026. The stock trades at 13.9x earnings, below the S&P 500's 22.8x.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 2:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Could Derail Bristol Myers Squibb Stock? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BMYBearishMed
01

Why it matters

The key trading variable is the guided magnitude and timing of Eliquis revenue step-down in 2027, which can drive multiple compression if growth is perceived to slow.

02

Market read

Quantified LOE-driven revenue risk for a blockbuster (Eliquis) is likely to be the dominant driver for near-term valuation debate around BMY’s growth trajectory.

03

What to watch

The article notes a 2026 adjusted EPS guide reduction tied to acquired research charges, net of licensing income, which may be less persistent than the Eliquis LOE impact.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning around the Oct. 29 earnings call guidance

Background

The piece centers on management commentary from an Oct. 29 call about Eliquis losing exclusivity in Europe and the resulting revenue pressure.

Company-level read

Ticker impact

$BMYBearishHigh confidence
Context

Bristol Myers Squibb warns Eliquis exclusivity loss in Europe will pressure sales in Q4 2026 and expects a 2027 revenue step down of $1.5B to $2B.

Expected impact

Likely downside bias as investors reprice 2027 revenue and margin expectations around the guided Eliquis step-down.

Evidence & confidence

The article cites management guidance for Eliquis revenue pressure and a quantified 2027 step down, which directly affects BMY’s growth outlook and valuation assumptions.

Market effects

Sector

Reinforces generic/LOE (loss of exclusivity) risk as a key valuation driver for large-cap pharma, especially for blockbuster anticoagulants.

Regional

Highlights Europe-specific exclusivity dynamics that can shift revenue mix and investor expectations for U.S.-listed pharma names.

Global

Could contribute to broader pharma sentiment if investors generalize the LOE risk across similar franchises.

Counterpoint

What could challenge this read

The Eliquis step-down is framed as a small slice of total revenue, while management points to growth-medicines momentum and $2B of efficiencies by end-2027.

Key entities

  • company
    Bristol Myers Squibb

    U.S.-listed pharma company whose guidance highlights Eliquis exclusivity loss in Europe and a 2027 revenue step down.

  • product
    Eliquis

    Bristol Myers Squibb’s major drug facing loss of exclusivity in Europe, with management expecting sales pressure in Q4 2026 and a 2027 step down.

Read at source← All news

Related articles

$BMYMed

Bristol says long-term Camzyos data buoys treatment in children

Bristol Myers Squibb reported 56-week trial data showing Camzyos (mavacamten) reduced LVOT gradient in children with obstructive hypertrophic cardiomyopathy. Continuous Camzyos treatment showed a -48.1 mmHg change, similar to placebo-to-Camzyos switch. Adverse events were more frequent in the continuous Camzyos group.

tradingview.com
$BMYMed

Bristol Myers Squibb presents 56-week Camzyos trial data

Bristol Myers Squibb (BMY) presented 56-week trial data for Camzyos in pediatric patients with obstructive hypertrophic cardiomyopathy. The study showed significant reductions in left ventricular outflow tract gradient with no severe adverse events. Camzyos received FDA approval for pediatric use in 2026. Additional data will be presented at the American Heart Association's Scientific Sessions 2026.

investing.com
$BMYMed

No teen on Bristol Myers Squibb’s heart drug had heart-pumping function fall below 50% in 56 weeks

Bristol Myers Squibb's Camzyos showed consistent efficacy and safety in a 56-week Phase 3 trial for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). No patient had left ventricular ejection fraction fall below 50%. The trial included a 28-week placebo-controlled period and demonstrated significant reductions in Valsalva left ventricular outflow tract gradient. Additional data will be presented at the American Heart Association’s Scientific Sessions 2026.

stocktitan.net
$BMYMed

New Treatment Option for Adults and Pediatric Patients Weighing 30 kg (66 lbs) or More With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The FDA approved Bristol Myers Squibb's CAMZYOS (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and pediatric patients weighing 30 kg or more. The approval follows positive results from the SCOUT-HCM trial, showing significant reductions in LVOT gradient and symptom improvements. CAMZYOS is the first FDA-approved therapy for pediatric oHCM.

hcplive.com